A recent case report described the development of CML in a person with CLL treated with ibrutinib who subsequently was treated with venetoclax, a BCL-2 inhibitor, with a clinical response [8]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.